Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients

• DOI: 10.1186/s12876-017-0613-x
• Publication Date: 2017-04-16T23:43:00Z
• Authors: Kessarin Thanapirom; Sirinporn Suksawa...; Wattana Sukeepais...; Pisit Tangkijvanich; Sombat Treepraser...; Panarat Thaimai; Rujipat Wasitthan...; Yong Poovorawan; Piyawat Komolmit
• Keywords: Pegylated interferon; Hepatitis C

Patients with chronic hepatitis C (HCV) infection have high prevalence of vitamin D deficiency. Genome-wide association study data has showed that several genetic variants within cascade affect function. This aimed to determine whether polymorphisms genes in the pathway are associated treatment responses pegylated interferon (PEG-IFN)-based therapy patients HCV infection. The included 623 Thai from 2 university hospitals diagnosed who were treated a PEG-IFN and ribavirin. genotyped for functional on synthetic including GC (rs4588, rs7041, rs22020, rs2282679), CYP2R1 (rs2060793, rs12794714), CYP27B1 (rs10877012), DHCR7 (rs12785878). Pre-treatment predictors sustained virologic response (SVR) at 24 weeks following discontinuation identified using logistic regression analysis. SVR was achieved by 60.5% (52.9% genotype 1; 66.7% non-genotype 1). In 44.6% 1-infected patients, only variant rs12785878 locus significantly an SVR. 1 had GT/TT higher rate than those GG allele (59.7% vs. 43.4%, P = 0.03), but did not differ between two groups (63.3% 59.1% allele, 0.54). By multivariate analysis, liver fibrosis stage 0–1 (OR 5.00; 95% CI, 2.02–12.37; < 0.001), 2.69; 1.03–7.05; 0.04) independent pre-treatment PEG-IFN-based patients. Baseline RNA 400,000 IU/ml 1.96; 1.13–3.39; 0.02) predictor GC, outcome even or polymorphism may be predictive marker